RaQualia Pharma (TSE:4579) Cyclically Adjusted Book per Share: 円252.54 (As of Mar. 2026)


TSE:4579 RaQualia Pharma Inc TSE:4579
57 GF Score
Price 円468.00
GF Value 円961.31
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is RaQualia Pharma Cyclically Adjusted Book per Share?

RaQualia Pharma TSE:4579 -2.70% 57 Cyclically Adjusted Book per Share is 円252.54 as of Mar. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 57/100 and a GF Value™ of 円961.31 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

RaQualia Pharma's adjusted book value per share for the three months ended in Mar. 2026 was 円310.812. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is 円252.54 for the trailing ten years ended in Mar. 2026.

During the past 12 months, RaQualia Pharma's average Cyclically Adjusted Book Growth Rate was -0.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -1.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of RaQualia Pharma was -1.40% per year. The lowest was -5.70% per year. And the median was -3.30% per year.

As of today (2026-07-08), RaQualia Pharma's current stock price is 円468.00. RaQualia Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was 円252.54. RaQualia Pharma's Cyclically Adjusted PB Ratio of today is 1.85.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of RaQualia Pharma was 5.23. The lowest was 1.32. And the median was 2.96.


RaQualia Pharma  (TSE:4579) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

RaQualia Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=468.00/252.54
=1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of RaQualia Pharma was 5.23. The lowest was 1.32. And the median was 2.96.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


RaQualia Pharma Cyclically Adjusted Book per Share Related Terms


RaQualia Pharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Cyclically Adjusted Book per Share Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 279.69 263.29 255.43 252.72 252.47

RaQualia Pharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 252.72 250.70 250.02 252.47 252.54

TSE:4579 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, RaQualia Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RaQualia Pharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where RaQualia Pharma's Cyclically Adjusted PB Ratio falls into.


TSE:4579
57GF Score
RaQualia Pharma Inc TSE:4579
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, RaQualia Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=310.812/112.7000*112.7000
=310.812

Current CPI (Mar. 2026) = 112.7000.

RaQualia Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201512 240.548 98.100 276.348
201603 242.482 97.900 279.139
201606 221.084 98.100 253.987
201609 205.965 98.000 236.860
201612 201.845 98.400 231.178
201703 200.868 98.100 230.763
201706 190.252 98.500 217.679
201709 181.402 98.800 206.923
201712 240.845 99.400 273.071
201803 225.235 99.200 255.887
201806 213.284 99.200 242.310
201809 203.471 99.900 229.541
201812 189.184 99.700 213.852
201903 185.857 99.700 210.091
201906 191.196 99.800 215.910
201909 181.026 100.100 203.812
201912 220.556 100.500 247.330
202003 203.074 100.300 228.180
202006 198.134 99.900 223.521
202009 186.988 99.900 210.946
202012 191.444 99.300 217.278
202103 201.322 99.900 227.117
202106 207.280 99.500 234.778
202109 200.837 100.100 226.117
202112 228.490 100.100 257.251
202203 222.496 101.100 248.025
202206 250.729 101.800 277.575
202209 250.095 103.100 273.382
202212 262.048 104.100 283.697
202303 289.365 104.400 312.370
202306 300.601 105.200 322.032
202309 288.445 106.200 306.099
202312 283.052 106.800 298.689
202403 277.208 107.200 291.430
202406 261.025 108.200 271.881
202412 255.083 110.700 259.692
202503 251.859 111.100 255.486
202506 257.061 111.700 259.362
202512 281.963 113.000 281.214
202603 310.812 112.700 310.812

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of 円252.54 mean?
RaQualia Pharma (TSE:4579) has a Cyclically Adjusted Book per Share of 円252.54 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Cyclically Adjusted Book per Share too high?
RaQualia Pharma's current Cyclically Adjusted Book per Share is 円252.54. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Cyclically Adjusted Book per Share compare to VRTX and REGN?
RaQualia Pharma's Cyclically Adjusted Book per Share of 円252.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Cyclically Adjusted Book per Share is 円252.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Cyclically Adjusted Book per Share is 円252.54. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Cyclically Adjusted Book per Share is 円252.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31. GuruFocus considers RaQualia Pharma to be Significantly Undervalued.

Key valuation signals for TSE:4579:

  • Cyclically Adjusted Book per Share: 円252.54
  • GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score

Get the complete analysis for TSE:4579

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円468.00
Price
円961.31
GF Value